Scotoma Reduction in AMD Patients Treated With Ranibizumab

Retina Research Foundation20 enrolled

Overview

This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.

Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Macular Degeneration

Interventions

intravitreal injection Lucentis (ranibizumab)DRUG

intravitreal injection Lucentis (ranibizumab)

Eligibility

Sex: ALLMin age: 50 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * BCVA \< 20/320 * Disciform macular degeneration wiht exudation Exclusion Criteria: * Non-amd CNV

Locations (1)

Retina Research Center

Slingerlands, New York, United States

Outcomes

Primary Outcomes

scotoma reduction

Time frame: 12 months

Secondary Outcomes

improved visual function

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.